Effects of Ramosetron on Gastrointestinal Transit of Guinea Pig.
- Author:
Yoo Mi PARK
1
;
Young Ju LEE
;
Young Ho LEE
;
Tae Il KIM
;
Hyojin PARK
Author Information
1. Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. hjpark21@yuhs.ac
- Publication Type:Original Article
- Keywords:
Gastrointestinal transit;
Mustard oil;
Ramosetron;
Serotonin 5-HT3 receptor antagonist;
Thyrotropin-releasing hormone
- MeSH:
Animals;
Benzimidazoles;
Charcoal;
Defecation;
Diarrhea;
Gastrointestinal Transit;
Guinea;
Guinea Pigs;
Humans;
Intestine, Small;
Irritable Bowel Syndrome;
Male;
Mustard Plant;
Plant Oils;
Pylorus;
Serotonin;
Thyrotropin-Releasing Hormone
- From:Journal of Neurogastroenterology and Motility
2013;19(1):36-41
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/AIMS: A selective 5-hydroxytryptamine (5-HT) type 3 receptor antagonist, ramosetron, inhibits stress-induced abnormal defecation in animals and is currently used as a therapeutic drug for irritable bowel syndrome with diarrhea. The aim of this study is to investigate the effect of ramosetron on altered gastrointestinal (GI) transit. METHODS: Male guinea pigs weighing approximately 300 g were used. The effect of ramosetron was investigated on altered GI transit induced by thyrotropin-releasing hormone (TRH), 5-HT, or mustard oil (MO). GI transit was evaluated by the migration of charcoal mixture from the pylorus to the most distal point, and expressed as a percentage (%) of charcoal migration (cm) of the total length of total small intestine (cm). RESULTS: The average charcoal transit was 51.3 +/- 20.1% in the control (vehicle) group, whereas in the ramosetron group charcoal moved 56.6 +/- 21.9%, 46.9 +/- 9.14% and 8.4 +/- 5.6% of the total small intestine at the concentrations of 10, 30 and 100 microg/kg, respectively. GI transit after administration of TRH (100 microg/kg), 5-HT (10 mg/kg) or MO (10 mg/kg) was accelerated compared to vehicle (5-HT, 94.9 +/- 9.22%; TRH, 73.4 +/- 14.7%; MO, 81.0 +/- 13.7%). Ramosetron inhibited GI transit altered by 5-HT, TRH or MO. CONCLUSIONS: Ramosetron modulated GI transit. We suggest that ramosetron may be therapeutically useful for those with accelerated upper GI transit.
